We have a diverse pipeline designed to make a meaningful difference for patients

TransCon Therapies in Development

Our pipeline of TransCon therapies is driven by the flexibility of this innovative drug development platform and our aim to improve patients’ lives. Today, Ascendis and its partners have multiple prodrug therapies in development. Each product candidate is unique and designed to be a best-in-class therapy.

Endocrinology Rare Diseases

Ascendis Programs	Clinical Trial	Status	Location

TransCon hGH

Turner syndrome (children aged 1–10)	United States	Phase 2	New InsiGHTS Trial NCT05690386
Multi-Indication (children aged 2–17) Turner syndrome, Idiopathic Short Stature (ISS), SHOX Deficiency, and Small for Gestational Age (SGA)	Multinational	Phase 3	HighLiGHts Trial NCT07221851

TransCon CNP

Achondroplasia (infants aged 0–<2)	Multinational	Pivotal Phase 2	reACHin Trial NCT06079398
Achondroplasia (children aged 2–11)	Multinational	Pivotal Phase 2	ApproaCH Trial NCT05598320
Achondroplasia (adolescents aged 12–18)	Multinational	Pivotal Phase 2b	teACH Trial NCT06732895
Achondroplasia (children & adolescents)	Multinational	Open Label Extension Trial	AttaCH Trial NCT05929807